We estimate revenue CAGR of ~17% over FY25-28E with EBITDA margin improving gradually to...
ICICI Direct Research Reports
ZF combines high margin technology products with a stable and growing aftermarket business, providing...
Asset quality remains a key strength for Capri Global, supported by its predominantly secured...
Volume growth expected at ~13% CAGR over FY25-28E; Doubling capacity by FY29E
SHL has the capability to manufacture oral liquids, tablets, injectables, dry powder & inhaler...
Ahluwalia enjoys a healthy balance sheet and is a net cash company
EIL is strategically skewing towards consultancy and cost-plus/OBE turnkey contracts, protecting margins from cost...
We expect Revenue and PAT to grow at 29.8% and 32.8% CAGR over FY25-FY28E.
Jubilant Pharmova (JPL) is an integrated, multi-dimensional pharmaceuticals company with global presence.
The company has maintained a healthy order book of ₹ 1685 crore (as on...
